DocumentRX-9524
Issued
Read3 min

UCLA Stem Cell Vesicles Keep 55% of Mice Diabetes-Free for 90 Days

UCLA's Nature Nanotechnology paper reports iPSC-derived vesicles in an HA hydrogel kept 55% of mice diabetes-free over 90 days, with a 3.4-fold gain in scalable manufacturing.

TAG P-7283 · 619 words on the filing

Type 1 Diabetes Delayed in Mice by Stem Cell-Derived Vesicles That Calm Immune Response
Type 1 Diabetes Delayed in Mice by Stem Cell-Derived Vesicles That Calm Immune ResponseAI-generated

Summary of findings

  • 55% of mice receiving iPSC vesicles in hydrogel stayed diabetes-free across a 90-day study.
  • Study published in Nature Nanotechnology; senior author Song Li, PhD, UCLA.
  • Suspension culture increased vesicle production 3.4-fold per million cells.
  • Hydrogel uses hyaluronic acid and Pluronic F127; both common in biomedical formulations.
  • PSC vesicles carry ROR1, CD133 and miR-302 family cargo absent from MSC vesicles.

Fifty-five percent of mice receiving stem cell-derived vesicles in an injectable hydrogel remained diabetes-free at the end of a 90-day study, UCLA researchers report in Nature Nanotechnology. That figure comes from an antigen-specific mouse model, not a human trial, and the authors themselves flag dosing, durability and infection risk as unanswered questions.

The paper, titled "Pluripotent stem cell-derived extracellular vesicles for systemic immune modulation in diabetes therapy," comes from a team led by Song Li, PhD, professor of bioengineering at UCLA Samueli and a member of the UCLA Broad Stem Cell Research Center. The core idea borrows from pregnancy: the maternal immune system tolerates an embryo carrying paternal genetic material, and the team asked whether vesicles from pluripotent stem cells — which share characteristics with early embryonic cells — carry that tolerogenic property.

How did the vesicles perform in cell studies?

In experiments with mouse and human immune cells, vesicles from embryonic stem cells and induced pluripotent stem cells outperformed those from mesenchymal stem cells, the long-studied benchmark in the field. The authors stated they saw stronger suppression of proinflammatory cytokine secretion, reduced T cell activation and induction of regulatory T cells.

The particles carry a distinct cargo: unique proteins and microRNAs absent from MSC-derived vesicles, including the pluripotency-associated proteins ROR1 and CD133 and members of the miR-302 family. Whether that cargo is what drives the effect, or merely travels alongside it, remains mechanistically unresolved.

What did the mouse model show?

The researchers introduced insulin-producing-cell-attacking immune cells into mice, then treated the animals with iPSC-derived vesicles. Because free vesicles clear rapidly from subcutaneous tissue, the team built an injectable hydrogel of hyaluronic acid and Pluronic F127 that gels at body temperature and releases particles over several days. Both polymers are already widely used in biomedical formulations, which the authors say supports translational potential.

Two local injections near the neck — placed to reach nearby lymph nodes — significantly delayed diabetes onset versus untreated controls. Hydrogel-treated animals showed more regulatory T cells in draining lymph nodes, systemic immune modulation and preserved β-cell mass. "One thing that surprised us was that a local injection could provide protection throughout the body," Li said. "That's the beauty of this approach."

Can the platform scale?

The team tackled manufacturing by growing PSCs as floating aggregates in gently moving liquid rather than on flat surfaces, avoiding differentiation into embryoid bodies. Suspension culture increased vesicle output 3.4-fold per million cells while preserving particle characteristics. iPSCs, which multiply extensively in the lab, could offer a more consistent and scalable source than adult stem cells with limited growth potential — a real consideration if GMP production is ever on the table.

What is still unknown?

Plenty. The work is preclinical, and safety and efficacy in humans are untested. Li sees the clearest fit in early-stage type 1 diabetes: "In the early stages, you still have some pancreatic cells left," he said. "If you can regulate the immune cells, you may be able to keep the remaining cells functional." In advanced disease, immune modulation cannot replace lost cells, though it might protect transplanted insulin-producing cells from rejection.

Next steps include larger animal models, dosing studies, long-term effectiveness and whether the treatment blunts defenses against infection. "Nature has designed something amazing," Li said of the embryo-tolerance analogy. "If we can better understand how an embryo avoids rejection by the mother's immune system, it could be very useful for a lot of immune-related diseases." The authors' own conclusion is measured: the findings "establish PSC EVs as a scalable immunomodulatory platform" — a claim the next round of studies will have to defend.

via doi.org (Original)

Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

18 articles

Linked filings

  1. K-2175
  2. K-2547
  3. E-3628
  4. K-8037
  5. K-7707

« Previous filing